B. Braun Medical – Recall of ceftazidime injection

- On April 25, 2019, B. Braun Medical announced a voluntary user-level recall of one lot of ceftazidime injection because the recalled lot contained elevated high molecular weight polymers (HMWPs). Additional tests for the recalled lot also indicated levels that were out of trend when compared with prior stability data.

- The recall includes the following product:

Product Description	NDC#	Lot# (Expiration Date)
Ceftazidime for injection (2 g) and dextrose injection (50 mL), duplex container	00264-3145-11	H8A832 (1/31/2020)

- Ceftazidime for injection and dextrose injection is indicated for the treatment of certain infections (ie, lower respiratory tract, skin and skin structure, bacterial septicemia, bone and joint, gynecological, and intra-abdominal) when caused by susceptible bacteria.

- Per B. Braun Medical, elevated levels of HMWP have been shown to cause acute nephrotoxicity in rabbits and mice and phagocytic deposits of foreign material in liver cells of dogs after repeated elevated doses. While the impact of HMWPs in humans is unknown, B. Braun Medical is initiating this recall out of an abundance of caution to prevent any risks of adverse reactions due to the elevated HMWP levels.

- To date, B. Braun Medical has not received any complaints or adverse reactions associated with the recalled product.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled ceftazidime injection.

- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.

- For more information regarding this recall, contact B. Braun Medical at **1-800-854-6851**.